<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Clin Endocrinol (Oxf)</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin. Endocrinol. (Oxf)</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1365-2265</journal-id>
<journal-id journal-id-type="publisher-id">CEN</journal-id>
<journal-title-group>
<journal-title>Clinical Endocrinology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0300-0664</issn>
<issn pub-type="epub">1365-2265</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27362444</article-id>
<article-id pub-id-type="pmc">5324561</article-id>
<article-id pub-id-type="doi">10.1111/cen.13149</article-id>
<article-id pub-id-type="publisher-id">CEN13149</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
<subj-group subj-group-type="heading">
<subject>Editor's Choice</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular spectrum of <styled-content style="fixed-case">TSH</styled-content>β subunit gene defects in central hypothyroidism in the UK and Ireland</article-title>
<alt-title alt-title-type="left-running-head"><italic>A. K. Nicholas</italic> et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="cen13149-cr-0001">
<name>
<surname>Nicholas</surname>
<given-names>A.K.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0002">
<name>
<surname>Jaleel</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0003">
<name>
<surname>Lyons</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0004">
<name>
<surname>Schoenmakers</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0005">
<name>
<surname>Dattani</surname>
<given-names>M.T.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0006">
<name>
<surname>Crowne</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0007">
<name>
<surname>Bernhard</surname>
<given-names>B.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0008">
<name>
<surname>Kirk</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0009">
<name>
<surname>Roche</surname>
<given-names>E.F.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="cen13149-aff-0007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cen13149-cr-0010">
<name>
<surname>Chatterjee</surname>
<given-names>V.K.</given-names>
</name>
<xref ref-type="aff" rid="cen13149-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="cen13149-cr-0011">
<name>
<surname>Schoenmakers</surname>
<given-names>N.</given-names>
</name>
<address>
<email>naaa2@cam.ac.uk</email>
</address>
<xref ref-type="aff" rid="cen13149-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="cen13149-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">University of Cambridge Metabolic Research Laboratories</named-content>
<named-content content-type="organisation-division">Wellcome Trust‐Medical Research Council Institute of Metabolic Science</named-content>
<institution>Addenbrooke's Hospital</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">UK</country>
</aff>
<aff id="cen13149-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Paediatric Endocrinology &amp; Diabetes</named-content>
<named-content content-type="organisation-division">National Children's Hospital</named-content>
<institution>AMNCH</institution>
<named-content content-type="city">Dublin</named-content>
<country country="IE">Ireland</country>
</aff>
<aff id="cen13149-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">University College London Institute of Child Health</named-content>
<named-content content-type="organisation-division">Developmental Endocrinology Research Group</named-content>
<named-content content-type="organisation-division">Section of Genetics and Epigenetics in Health and Disease</named-content>
<institution>Genetics and Genomic Medicine Programme</institution>
<named-content content-type="city">London</named-content>
<country country="GB">UK</country>
</aff>
<aff id="cen13149-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Paediatric Endocrinology &amp; Diabetes</named-content>
<named-content content-type="organisation-division">Bristol Royal Hospital for Children</named-content>
<institution>University Hospitals Bristol NHS Foundation Trust</institution>
<named-content content-type="city">Bristol</named-content>
<country country="GB">UK</country>
</aff>
<aff id="cen13149-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Genetics</named-content>
<institution>North West Thames Regional Genetics Service</institution>
<institution>North West London Hospitals NHS Trust</institution>
<named-content content-type="city">Harrow</named-content>
<country country="GB">UK</country>
</aff>
<aff id="cen13149-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Endocrinology</named-content>
<institution>Birmingham Children's Hospital</institution>
<named-content content-type="city">Birmingham</named-content>
<country country="GB">UK</country>
</aff>
<aff id="cen13149-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">University of Dublin</named-content>
<institution>Trinity College Dublin</institution>
<named-content content-type="city">Dublin</named-content>
<country country="IE">Ireland</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>Correspondence: Nadia Schoenmakers, University of Cambridge Metabolic Research Laboratories, Level 4, Wellcome Trust‐MRC Institute of Metabolic Science, Box 289, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. Tel.: +44 1223 767188; Fax: +44 1223 330598; E‐mail: <email>naaa2@cam.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2017</year>
</pub-date>
<volume>86</volume>
<issue>3</issue>
<issue-id pub-id-type="doi">10.1111/cen.2017.86.issue-3</issue-id>
<fpage>410</fpage>
<lpage>418</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>24</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>24</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>6</month>
<year>2016</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2016 The Authors. <italic>Clinical Endocrinology</italic> Published by John Wiley &amp; Sons Ltd.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:CEN-86-410.pdf" xlink:type="simple"></self-uri>
<abstract id="cen13149-abs-0001">
<title>Summary</title>
<sec id="cen13149-sec-0001">
<title>Objective</title>
<p>Homozygous mutations in the <styled-content style="fixed-case">TSH</styled-content> beta subunit gene (<italic><styled-content style="fixed-case">TSHB</styled-content></italic>) result in severe, isolated, central congenital hypothyroidism (<styled-content style="fixed-case">CCH</styled-content>). This entity evades diagnosis in <styled-content style="fixed-case">TSH</styled-content>‐based congenital hypothyroidism (<styled-content style="fixed-case">CH</styled-content>) screening programmes in the <styled-content style="fixed-case">UK</styled-content> and Ireland. Accordingly, genetic diagnosis, enabling ascertainment of affected relatives in families, is critical for prompt diagnosis and treatment of the disorder.</p>
</sec>
<sec id="cen13149-sec-0002">
<title>Design, Patients and Measurements</title>
<p>Four cases of isolated <styled-content style="fixed-case">TSH</styled-content> deficiency from three unrelated families in the <styled-content style="fixed-case">UK</styled-content> and Ireland were investigated for mutations or deletions in <italic><styled-content style="fixed-case">TSHB</styled-content></italic>. Haplotype analysis, to investigate a founder effect, was undertaken in cases with identical mutations (c.373delT).</p>
</sec>
<sec id="cen13149-sec-0003">
<title>Results</title>
<p>Two siblings in kindred 1 were homozygous for a previously described <italic><styled-content style="fixed-case">TSHB</styled-content></italic> mutation (c.373delT). In kindreds 2 and 3, the affected individuals were compound heterozygous for <italic><styled-content style="fixed-case">TSHB</styled-content></italic> c.373delT and either a 5·4‐<styled-content style="fixed-case">kB </styled-content>
<italic><styled-content style="fixed-case">TSHB</styled-content></italic> deletion (kindred 2, c.1‐4389_417*195delins<styled-content style="fixed-case">CTCA</styled-content>) or a novel TSHB missense mutation (kindred 3, c.2T&gt;C, p.Met1?). Neurodevelopmental retardation, following delayed diagnosis and treatment, was present in 3 cases. In contrast, the younger sibling in kindred 1 developed normally following genetic diagnosis and treatment from birth.</p>
</sec>
<sec id="cen13149-sec-0004">
<title>Conclusions</title>
<p>This study, including the identification of a second, novel, <italic><styled-content style="fixed-case">TSHB</styled-content></italic> deletion, expands the molecular spectrum of <italic><styled-content style="fixed-case">TSHB</styled-content></italic> defects and suggests that allele loss may be a commoner basis for <styled-content style="fixed-case">TSH</styled-content> deficiency than previously suspected. Delayed diagnosis and treatment of profound central hypothyroidism in such cases result in neurodevelopmental retardation. Inclusion of thyroxine (T4) plus thyroxine‐binding globulin (<styled-content style="fixed-case">TBG</styled-content>), or free thyroxine (<styled-content style="fixed-case">FT</styled-content>4) in <styled-content style="fixed-case">CH</styled-content> screening, together with genetic case ascertainment enabling earlier therapeutic intervention, could prevent such adverse sequelae.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>Wellcome Trust</funding-source>
<award-id>100585/Z/12/Z</award-id>
<award-id>095564/Z/11/Z</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>National Institute for Health Research Biomedical Research Centre Cambridge</funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="1"></table-count>
<page-count count="9"></page-count>
<word-count count="5718"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>cen13149</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>March 2017</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.7 mode:remove_FC converted:24.02.2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="cen13149-sec-0005">
<title>Introduction</title>
<p>Isolated congenital central hypothyroidism is rare (incidence 1 in 65 000),<xref ref-type="ref" rid="cen13149-bib-0001">1</xref> with genetic causes comprising mutations in the TSH beta subunit (<italic>TSHB</italic>), the immunoglobulin superfamily member 1 (<italic>IGSF1</italic>) or, less frequently, the TRH receptor (<italic>TRHR</italic>) genes.<xref ref-type="ref" rid="cen13149-bib-0002">2</xref> Central hypothyroidism is associated with either subnormal or inappropriately normal TSH levels and therefore evades diagnosis in the UK and Irish TSH‐based newborn screening programmes for congenital hypothyroidism (CH). Unfortunately, patients may then present later in the neonatal period with overt clinical hypothyroidism; in <italic>TSHB</italic> mutation cases, thyroid hormone deficiency is profound, resulting in neurodevelopmental retardation.<xref ref-type="ref" rid="cen13149-bib-0003">3</xref>
</p>
<p>Heterodimeric TSH, secreted by anterior pituitary thyrotroph cells, comprises a hormone‐specific beta subunit (TSHβ) and a common alpha subunit (αGSU) shared with other members of the glycoprotein hormone family (luteinizing hormone, follicle‐stimulating hormone and chorionic gonadotrophin). The integrity and bioactivity of the heterodimer are maintained by a ‘seat belt’ structure formed by the β‐subunit peptide that is stabilized by disulphide bridges including the so‐called buckle between amino acids 39 and 125.<xref ref-type="ref" rid="cen13149-bib-0004">4</xref>
</p>
<p>The human TSHβ subunit gene is organized into 3 exons: exon 1 is untranslated, and exons 2 and 3 encode a 138‐amino acid peptide. The twenty N‐terminal amino acids encode a signal peptide that is cleaved to yield a 118‐amino acid mature protein detectable in serum.<xref ref-type="ref" rid="cen13149-bib-0004">4</xref>, <xref ref-type="ref" rid="cen13149-bib-0005">5</xref> The most frequently described <italic>TSHB</italic> mutation is a single‐nucleotide deletion (c373delT), resulting in a cysteine 125 to valine conversion (C125V) and disruption of the Cys‐Cys 39–125 disulphide bridge, with a subsequent shift in reading frame and premature stop codon at position 134.<xref ref-type="ref" rid="cen13149-bib-0006">6</xref> Eight additional mutations have been described, including missense (p.C108Y, p.C105R, p.G49R) and nonsense or frameshift mutations (p.E32*, p.Q69*, p.F77Sfs*6).<xref ref-type="ref" rid="cen13149-bib-0003">3</xref>, <xref ref-type="ref" rid="cen13149-bib-0007">7</xref>, <xref ref-type="ref" rid="cen13149-bib-0008">8</xref>, <xref ref-type="ref" rid="cen13149-bib-0009">9</xref>, <xref ref-type="ref" rid="cen13149-bib-0010">10</xref>, <xref ref-type="ref" rid="cen13149-bib-0011">11</xref> Two splice site mutations (c162G&gt;A, IVS2 + 5 G&gt;A),<xref ref-type="ref" rid="cen13149-bib-0003">3</xref>, <xref ref-type="ref" rid="cen13149-bib-0012">12</xref> and more recently a homozygous <italic>TSHB</italic> deletion, have also been reported.<xref ref-type="ref" rid="cen13149-bib-0013">13</xref> All are inherited in an autosomal recessive manner and are associated with severe central hypothyroidism. (The nomenclature of mutations in this paper follows the most recent HGNC guidelines to include the 20‐amino acid signal peptide of TSHβ, such that codon numbering may differ from that cited in the previously published articles).</p>
<p>We report three kindreds from the UK or Ireland in which four cases exhibit isolated central hypothyroidism secondary to <italic>TSHB</italic> mutations. In kindred 1, two siblings (P1a and P1b) are homozygous for the previously described c.373delT mutation. In kindred 2, the affected child (P2) is compound heterozygous for c.373delT together with a maternally derived 5·4‐kb deletion involving <italic>TSHB</italic> alone (c.1‐4389_417*195delinsCTCA). In kindred 3, the proband (P3) is compound heterozygous for c.373delT and a novel missense mutation (c.2T&gt;C, p.Met1?), disrupting the methionine residue from which translation is initiated. We describe these <italic>TSHB</italic> defects and associated clinical phenotypes in the context of the wider literature.</p>
</sec>
<sec id="cen13149-sec-0006">
<title>Patients and methods</title>
<p>Clinical phenotype, auxological parameters and biochemistry for each case are summarized in Table <xref ref-type="table-wrap" rid="cen13149-tbl-0001">1</xref>.</p>
<table-wrap id="cen13149-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Clinical phenotype, auxological and biochemical parameters for each case harbouring <italic>TSHB</italic> mutations</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">P1a</th>
<th align="left" colspan="1" rowspan="1" valign="top">P1b</th>
<th align="left" colspan="1" rowspan="1" valign="top">P2</th>
<th align="left" colspan="1" rowspan="1" valign="top">P3</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Neonatal screening TSH (mU/l)</td>
<td align="left" colspan="1" rowspan="1">‘Normal’</td>
<td align="left" colspan="1" rowspan="1">‘Normal’</td>
<td align="left" colspan="1" rowspan="1">&lt;1</td>
<td align="left" colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gestational length (weeks)</td>
<td align="left" colspan="1" rowspan="1">42</td>
<td align="left" colspan="1" rowspan="1">42</td>
<td align="left" colspan="1" rowspan="1">40</td>
<td align="left" colspan="1" rowspan="1">39</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Birth weight (kg)</td>
<td align="left" colspan="1" rowspan="1">3·71</td>
<td align="left" colspan="1" rowspan="1">4·14</td>
<td align="left" colspan="1" rowspan="1">3·18</td>
<td align="left" colspan="1" rowspan="1">2·8</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">At diagnosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Age (weeks)</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Birth</td>
<td align="left" colspan="1" rowspan="1">8</td>
<td align="left" colspan="1" rowspan="1">14</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Body length (cm) and centile</td>
<td align="left" colspan="1" rowspan="1">56·2 (25th)</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">51 (&lt;3rd)</td>
<td align="left" colspan="1" rowspan="1">&lt;3rd</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Body weight (kg) and centile</td>
<td align="left" colspan="1" rowspan="1">5·60 (75th)</td>
<td align="left" colspan="1" rowspan="1">4·14 (75th)</td>
<td align="left" colspan="1" rowspan="1">3·52 (&lt;3rd)</td>
<td align="left" colspan="1" rowspan="1">NA(3rd)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">TSH (mU/l)</td>
<td align="left" colspan="1" rowspan="1">0·1(0·1–5·0)</td>
<td align="left" colspan="1" rowspan="1">&lt;0·05(0·3–4·0)</td>
<td align="left" colspan="1" rowspan="1">2·78 (0·4–4·0)</td>
<td align="left" colspan="1" rowspan="1">0·45 (0·4–3·5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">fT4 (pmol/l)</td>
<td align="left" colspan="1" rowspan="1">&lt;10(50–160)<xref ref-type="fn" rid="cen13149-note-0001">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">6·5(10–24)</td>
<td align="left" colspan="1" rowspan="1">&lt;3·89(10–25)</td>
<td align="left" colspan="1" rowspan="1">&lt;5·1 (13·8–22·5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Peak TSH response to TRH</td>
<td align="left" colspan="1" rowspan="1">0·09</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">3·21</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MRI pituitary</td>
<td align="left" colspan="1" rowspan="1">Normal</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">Normal</td>
<td align="left" colspan="1" rowspan="1">Normal</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">Extrathyroidal abnormalities</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Neurodevelopment</td>
<td align="left" colspan="1" rowspan="1">Mild motor and sensory processing deficits, extra support at school</td>
<td align="left" colspan="1" rowspan="1">Normal</td>
<td align="left" colspan="1" rowspan="1">Mild motor delay</td>
<td align="left" colspan="1" rowspan="1">
Horizontal pendular nystagmus, bilateral sensorineural hearing loss developmental delay (motor, language), Autism/Asperger spectrum<break></break>
Attends special school
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Haematological</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Macrocytic anaemia</td>
<td align="left" colspan="1" rowspan="1">Macrocytic anaemia</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="cen13149-note-0001">
<label>a</label>
<p>In P1a, the T4 value refers to total T4 (nmol/l). In three cases, the absolute T4 value could not be quantified because it was significantly below the lower limit of the normal reference range (P1a, 50–160 nmol/l, Ciba Corning ACS 180) or reportable range quoted by the assay manufacturer (P2 3·9pmol/l, Siemens Immulite 2500 SMS, P3 5·1pmol/l, Abbott AxSym Immunoassay).</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<sec id="cen13149-sec-0007">
<title>Patients 1a and 1b (P1a and P1b)</title>
<p>P1a is the second son of healthy, nonconsanguineous Caucasian (UK) parents. Although his TSH on neonatal screening was reported normal, he presented aged 3 weeks with a lower respiratory tract infection and was noted to have clinical features of hypothyroidism, including somnolence, constipation and dry skin. Thyroid function tests were consistent with severe central hypothyroidism (total T4 &lt; 10 nmol/l, normal range 50–160; TSH 0·1 mU/l, NR 0·1–5), with no TSH response to TRH stimulation. Subsequent dynamic testing, showing preserved corticotroph, somatotroph and gonadotroph function, excluded combined pituitary hormone deficiency (data not shown), and his basal prolactin level was 554 mU/l (NR &lt;700). Levothyroxine treatment was commenced at the age of 5 weeks and 2 days, despite good compliance development was delayed. Formal assessment of age 2 years revealed significantly impaired hearing and speech. At age 7 years, growth is normal, and he is in mainstream education, but requires additional support.</p>
<p>P1b, the younger brother of P1a, underwent screening for central hypothyroidism at birth following this diagnosis in his older sibling. Thyroid function was consistent with TSH deficiency (cord blood fT4 6·5 pmol/l, NR 10–24; TSH &lt;0·05 mU/l, NR 0·3–4). Levothyroxine was commenced at age 1 week, and he subsequently grew and developed normally. Both parents are clinically and biochemically euthyroid.</p>
</sec>
<sec id="cen13149-sec-0008">
<title>Patient 2 (P2)</title>
<p>P2 is the daughter of healthy, nonconsanguineous Caucasian (Irish) parents. Her TSH in neonatal screening was normal. She presented aged 8 weeks with prolonged jaundice, poor weight gain and feeding since birth, somnolence and constipation. She was clinically hypothyroid, with cool peripheries, hypotonia, an umbilical hernia, cutis marmorata, coarse facial features and macroglossia. Severe biochemical central hypothyroidism was confirmed (fT4 &lt; 3·89 pmol/l, NR 10–25; TSH 2·78 mU/l, NR 0·4–4·0). In a TRH stimulation test, the TSH response was absent, but prolactin levels rose (basal prolactin 723 mU/l, 20 min prolactin 1064 mU/l), suggesting a defect downstream of the TRH receptor. Dynamic evaluation of corticotroph and somatotroph function was normal. Following commencement of levothyroxine aged 8 weeks, her growth was normal. Despite good compliance with treatment, she exhibits mild motor delay at age 7 years. Both parents are clinically and biochemically euthyroid.</p>
</sec>
<sec id="cen13149-sec-0009">
<title>Patient 3 (P3)</title>
<p>P3 is the only daughter of healthy, nonconsanguineous Caucasian (UK) parents. Her TSH in neonatal screening was reported as normal. She presented aged 3·5 months with feeding difficulties, somnolence, constipation and severe growth retardation. She was clinically hypothyroid with a small umbilical hernia and depressed nasal bridge. Thyroid biochemistry confirmed profound central hypothyroidism (fT4 &lt; 5·1 pmol/l, NR 13·8–22·5; TSH 0·45 mU/l, NR 0·4–3·5). Subsequent evaluation of pituitary–adrenal, gonadotrophins and basal serum prolactin was normal. Although her growth response to levothyroxine treatment was excellent, she has multiple neurodevelopmental deficits including bilateral sensorineural deafness and nystagmus without optic nerve hypoplasia. Motor and language development was significantly delayed; at the age of 10 years, she is on the autistic/Asperger's spectrum. She has a statement of Special Educational Needs and is unable to attend mainstream school. Her mother is clinically and biochemically euthyroid; her father is not available for evaluation.</p>
</sec>
</sec>
<sec id="cen13149-sec-0010">
<title>Methods</title>
<p>All investigations were part of an ethically approved protocol and/or clinically indicated, being undertaken with the consent from patients and/or next of kin.</p>
<sec id="cen13149-sec-0011">
<title>Sanger sequencing of the <italic>TSHB</italic> subunit gene</title>
<p>Genomic DNA was extracted from peripheral blood leucocytes using the standard techniques. All three <italic>TSHB</italic> subunit gene exons and exon/intron boundaries were amplified by PCR using specific primers: 5’‐TCCAGGTAAAGATATTGTGAGCT‐3’ and 5’‐TTACAGCCTGTTGAAGCAAATT‐3’ (exon 1), 5’‐CCTAGATTTCTGAGTTAGCCCCT‐3’ and 5’‐TGCGTATCCATTGTGCTGAG‐3’ (exon 2) and 5’‐TGTTTCCTAAAGTCCTGTCACA‐3’ and 5’‐ACCTTCAACTGAGCCCAAAAG‐3’ (exon 3). To characterize the chromosomal deletion around <italic>TSHB</italic> in P3, the homozygous region delineated by SNP markers rs7523360 and rs1998008 was amplified by long‐range PCR using the primers 5’‐AACACACATCCAACATTCTTCCA‐3’ and 5’‐AAATCCCGCAGTAATTCTTTGCT‐3’.</p>
<p>PCR products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, USA) and 3730 DNA Analyzer (Applied Biosystems). The <italic>TSHB</italic> variants listed in this study are described using the systematic nomenclature approved by the Human Genome Variation Society (HGVS; <ext-link ext-link-type="uri" xlink:href="http://varnomen.hgvs.org">varnomen.hgvs.org</ext-link>). Nucleotide numbering starts from the A (+1) of the translation initiation codon (ATG) of the NCBI reference sequence NM_000549.4 and includes the 20‐amino acid signal peptide. Amino acid residues are numbered according to the NCBI reference sequence NP_000540.2.</p>
</sec>
<sec id="cen13149-sec-0012">
<title>Haplotype analysis</title>
<p>To determine chromosome 1 haplotypes, individuals were genotyped for single‐nucleotide polymorphisms with MAF &gt;0·38 from seven linkage disequilibrium blocks selected using Haploview (The Broad Institute, USA) and spanning 225 kb 5’ and 205 kb 3’ of the <italic>TSHB</italic> locus (Figure <xref ref-type="fig" rid="cen13149-fig-0003">3</xref>, primers available on request).</p>
</sec>
<sec id="cen13149-sec-0013">
<title>
<italic>In silico</italic> tools</title>
<p>
<italic>In silico</italic> analysis of the novel missense variant (c.2T&gt;C) was performed using Alamut as an interface (Interactive Biosoftware, Rouen, France) and the SignalP V4.1 signal peptide prediction package (<ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/SignalP">www.cbs.dtu.dk/services/SignalP</ext-link>) to determine whether translation from Met‐7 would alter the probability of the protein sequence acting as a signal peptide.<xref ref-type="ref" rid="cen13149-bib-0014">14</xref>
</p>
</sec>
<sec id="cen13149-sec-0014">
<title>TaqMan quantitative real‐time PCR (qPCR) analysis of <italic>TSHB</italic> gene copy number</title>
<p>The following intra‐exonic primer/probe sets were used to quantify genomic <italic>TSHB</italic> copy number and genomic <italic>THRA</italic> in P3, her parents, and 10 unrelated, euthyroid controls. <italic>TSHB</italic>: primer/probe set Hs02759015_s1 (ABI Life Technologies); THRA: forward 5’‐TTCGAGCACTACGTCAACCA‐3’; reverse 5’‐CCCGATCATGCGGAGGTCAG‐3’; probe 5’‐FAM CACAACATTCCGCACTTCTG‐TAMRA‐3’ using qPCR as previously described.<xref ref-type="ref" rid="cen13149-bib-0015">15</xref> The comparative Ct method was used to quantify genomic <italic>TSHB</italic> normalized to genomic <italic>THRA</italic>.</p>
</sec>
</sec>
<sec id="cen13149-sec-0015">
<title>Results</title>
<sec id="cen13149-sec-0016">
<title>
<italic>TSHB</italic> analysis using Sanger sequencing</title>
<p>P1a and P1b were homozygous for a single‐nucleotide deletion in <italic>TSHB</italic>, c.373delT, p.C125Vfs*10 (c.313delT, p.C105Vfs114X, legacy numbering), described previously, with both euthyroid parents being heterozygous. Despite paternal heterozygosity for this mutation, but wild‐type maternal <italic>TSHB</italic> sequence (Fig. <xref ref-type="fig" rid="cen13149-fig-0001">1</xref>a), P2 was apparently homozygous for the same mutation (p.C125Vfs*10). This suggested uniparental inheritance of the mutation, due to either paternal, uniparental disomy or a maternal deletion involving the <italic>TSHB</italic> locus. P3 was heterozygous for the p.C125Vfs*10 mutation and a novel missense mutation (c.2T&gt;C, p.Met1?), disrupting the start site for translation at the beginning of the signal peptide of TSHβ. As the maternal <italic>TSHB</italic> locus only showed heterozygosity for the c.2T&gt;C, p.Met1? change, these mutations were assumed to be compound heterozygous, occurring on separate alleles.</p>
<fig fig-type="Figure" id="cen13149-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>(a) Apparent uniparental inheritance of the <italic><styled-content style="fixed-case">TSHB</styled-content></italic> c.373delT mutation in P2: Chromatograms obtained from <italic><styled-content style="fixed-case">TSHB</styled-content></italic> sequencing in P2 and parents; P2 is homozygous for a single‐nucleotide deletion at position 373 (c.373delT), and her father is heterozygous for the mutation as predicted. Surprisingly, the maternal sequence is apparently wild type. (b) Decreased genomic <italic><styled-content style="fixed-case">TSHB</styled-content></italic> in P2 and her mother are consistent with a maternally inherited <italic><styled-content style="fixed-case">TSHB</styled-content></italic> deletion: TaqMan <styled-content style="fixed-case">qPCR</styled-content> was used to quantify genomic <italic><styled-content style="fixed-case">TSHB</styled-content></italic> normalized to genomic <italic><styled-content style="fixed-case">THRA</styled-content></italic> levels and expressed as a percentage of the mean for 10 euthyroid controls; levels in P2 and her mother are approximately fifty per cent of those in her father and controls, consistent with a heterozygous maternal genomic deletion at the <italic><styled-content style="fixed-case">TSHB</styled-content></italic> locus. <italic>P</italic>‐values were computed using a 2‐tailed Student's <italic>t</italic>‐test. (c) Single‐nucleotide polymorphism (<styled-content style="fixed-case">SNP</styled-content>) genotyping around the <italic><styled-content style="fixed-case">TSHB</styled-content></italic> locus defines the deleted region in P2: Schematic summarizing <styled-content style="fixed-case">SNP</styled-content> genotyping around the <italic><styled-content style="fixed-case">TSHB</styled-content></italic> locus. Light grey: <styled-content style="fixed-case">SNP</styled-content>s with obligate uniparental inheritance; dark grey: heterozygous <styled-content style="fixed-case">SNP</styled-content>s defining the boundaries of obligate diparental inheritance. Single bases in P2 define the region of loss of heterozygosity. (d) Maternally inherited deletion–insertion in P2: Schematic of the <italic><styled-content style="fixed-case">TSHB</styled-content></italic> locus and sequencing chromatogram defining the maternal deletion–insertion for which P2 was compound heterozygous.</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="CEN-86-410-g001"></graphic>
</fig>
</sec>
<sec id="cen13149-sec-0017">
<title>Investigation to define the <italic>TSHB</italic> deletion in P2</title>
<p>TaqMan qPCR was used to quantify <italic>TSHB</italic> copy number in P2, her parents, and ten unrelated, euthyroid controls. The results, showing a fifty per cent decrease in amplified signal from the <italic>TSHB</italic> locus in P2 and her mother, were consistent with a maternal, heterozygous <italic>TSHB</italic> deletion (Fig. <xref ref-type="fig" rid="cen13149-fig-0001">1</xref>b).</p>
<p>P2 and both parents were genotyped for single‐nucleotide polymorphisms around the <italic>TSHB</italic> locus. This analysis delineated a 211‐Kb region with loss of heterozygosity at 1p13·2, with heterozygous SNPs confirming obligate biparental inheritance at the boundaries of this interval. An informative SNP (rs1321108), 4·4 kb proximal to <italic>TSHB</italic>, confirmed uniparental (paternal) inheritance at this site (A/A), as no maternal allele (G/G) was inherited (Fig. <xref ref-type="fig" rid="cen13149-fig-0001">1</xref>c). Subsequent Sanger sequencing of the region, using a long‐range PCR, confirmed a 5·4‐kb maternal deletion involving only the <italic>TSHB</italic> locus, together with a 4‐bp insertion (c.1‐4389_417*195delinsCTCA) (Fig. <xref ref-type="fig" rid="cen13149-fig-0001">1</xref>d).</p>
</sec>
<sec id="cen13149-sec-0018">
<title>
<italic>In silico</italic> prediction of the deleterious consequences of the c.2T&gt;C mutation in P3</title>
<p>P3 exhibits a novel missense mutation (c.2T&gt;C), in which a methionine codon, from which translation is initiated, is replaced by a threonine. This mutation was absent from the published normal genome data sets (dBSNP, 1000 Genomes, Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>), April 8th, 2016). Alamut predictive software suggests that this substitution will adversely affect translation of the TSHβ polypeptide.</p>
<p>In higher eukaryotes, efficient initiation of translation is governed by the nucleotide sequence surrounding the ATG start codon (GCCGCC<bold>A/G</bold>CC<underline underline-style="single"><italic>A</italic>UG</underline>
<bold>G,</bold> initiator codon underlined), with a purine (usually A) at position ‐3 (5’) and guanine at position +4 (3’), relative to the adenine (A) of the initiator codon (Fig. <xref ref-type="fig" rid="cen13149-fig-0002">2</xref>a).<xref ref-type="ref" rid="cen13149-bib-0016">16</xref> Thus, although there is an alternative, in‐frame, ATG start codon at Met‐7, the nucleotide sequence surrounding Met‐7 (CTCTTT<bold>C</bold>TG<underline underline-style="single"><italic>A</italic>TG</underline>
<bold>T</bold>) lacks both a purine at position ‐3 (C, bold) and a guanine at position +4 (T, bold), suggesting that efficient translation from this alternative site is unlikely. Additionally, as the first 20 amino acids of TSHβ form a signal peptide, even if limited synthesis from Met‐7 of TSHβ occurs, the resulting N‐terminally deleted TSHβ polypeptide would lack hydrophobic residues within its signal sequence that may be critical for correct protein translocation (Fig <xref ref-type="fig" rid="cen13149-fig-0002">2</xref>a).<xref ref-type="ref" rid="cen13149-bib-0017">17</xref> SignalP 4.1 software<xref ref-type="ref" rid="cen13149-bib-0014">14</xref> also predicts that if translation occurred from Met‐7, the ability to appropriately cleave signal peptide from TSHβ polypeptide would be lost (Fig. <xref ref-type="fig" rid="cen13149-fig-0002">2</xref>b). Taken together, these features suggest that the c.2T&gt;C <italic>TSHB</italic> mutation is likely to result in significantly impaired biosynthesis of functional TSHβ polypeptide.</p>
<fig fig-type="Figure" id="cen13149-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>(a) Schematic summarizing the deleterious c. 2T&gt;C and c.373delT mutations in P3: Sequencing chromatograms are aligned with a schematic of the <italic><styled-content style="fixed-case">TSHB</styled-content></italic> gene to show the position of the compound heterozygous mutations. The amino acid sequence of the <styled-content style="fixed-case">TSHB</styled-content> signal peptide contains a putative hydrophobic core (underlined) and cleavage site (double vertical line). Translation from Met‐7 due to the c.2T&gt;C mutation would result in loss of the N‐terminal portion of the peptide and hydrophobic residues, with the resultant amino acid sequence, highlighted in grey. The <styled-content style="fixed-case">cDNA</styled-content> nucleotide sequence around Met‐1 and Met‐7 is shown beneath, with the bases at positions ‐3 and +4 in bold type, defining favourable (Met‐1) and unfavourable (Met‐7) Kozak sequences for translation initiation. (b) Translation from Met‐7 is likely to abrogate the <italic><styled-content style="fixed-case">TSHB</styled-content></italic> signal peptide: Signal P 4.0 analysis output for wild‐type <italic><styled-content style="fixed-case">TSHB</styled-content></italic>, and <italic><styled-content style="fixed-case">TSHB</styled-content></italic> lacking the first 6 amino acids (i.e. the putative peptide generated if translation occurs from Met‐7). The presence of a signal peptide is predicted by scoring every residue (‘S‐score’) for the stretch of amino acids analysed. The predicted score for the signal peptidase cleavage site is indicated by the C‐score. Y‐score is a composite score for C‐ and S‐scores, to improve cleavage site prediction. The D‐score (discrimination score) is a weighted average of the mean S and the max. Y scores and is used to discriminate signal peptides from nonsignal peptides, with a value of &gt;0·45 taken to predict a signal peptide (<ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/SignalP-4.0/output.php">www.cbs.dtu.dk/services/SignalP-4.0/output.php</ext-link>). Wild‐type <styled-content style="fixed-case">TSHB</styled-content> (upper panel) is strongly predicted to contain a cleavable signal peptide within residues 1–20 (C‐score 0·62, Y‐score 0·76, S‐score 0·97, D‐score 0·853), whereas this prediction becomes much weaker when Met‐7 is used as the translational start site (lower panel), and no clear cleavage site is denoted (C‐score 0·13, Y‐score 0·24, S‐score 0·52, D‐score 0·334).</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="CEN-86-410-g002"></graphic>
</fig>
</sec>
<sec id="cen13149-sec-0019">
<title>Haplotype analysis around the <italic>TSHB</italic> c.373delT mutation</title>
<p>Genotyping for single‐nucleotide polymorphisms around <italic>TSHB</italic> indicates that all four cases share an extended haplotype for the c.373delT mutation, suggesting common ancestry (Fig. <xref ref-type="fig" rid="cen13149-fig-0003">3</xref>a,b). Intriguingly, all of the UK cases may be of Irish descent; P3, with presumed paternal inheritance of c.373delT, confirms paternal Irish descent; P1a and P1b also acknowledge paternal Irish ancestry.</p>
<fig fig-type="Figure" id="cen13149-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>(a) The c.373delT mutation occurs on a common haplotype in all 3 kindreds: Table showing the chromosomal location of genotyped <styled-content style="fixed-case">SNP</styled-content>s, and the genotype of probands and parents. The maternal alleles inherited by the probands are shown in grey italics. P: proband; M: mother; F: father; cells with grey fill: inheritance unclear. (b) Schematic showing the chromosomal location of genotyped <styled-content style="fixed-case">SNP</styled-content>s, within seven blocks 1–7 that are in tight linkage disequilibrium and their position relative to <italic><styled-content style="fixed-case">TSHB</styled-content></italic> and neighbouring <italic><styled-content style="fixed-case">SYCP</styled-content>1</italic> and <italic><styled-content style="fixed-case">TSPAN</styled-content>2</italic> genes. The location of the c.373delT mutation is denoted by a star.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="CEN-86-410-g003"></graphic>
</fig>
</sec>
</sec>
<sec id="cen13149-sec-0020">
<title>Discussion</title>
<p>This report represents first documentation of three different <italic>TSHB</italic> mutations in patients from the UK and Ireland exhibiting characteristic clinical features, although two American cases of Scottish–Irish ancestry have been described.<xref ref-type="ref" rid="cen13149-bib-0018">18</xref> Neurodevelopmental retardation is a consistent feature in <italic>TSHB</italic> mutation cases, often attributed to delayed diagnosis and initiation of treatment, as these individuals are not detected in TSH‐based, CH screening programmes.<xref ref-type="ref" rid="cen13149-bib-0003">3</xref> Thus, in our patients, severity of neurodevelopmental impairment correlates with the age of thyroxine commencement: in P3, who was diagnosed aged 3·5 months, neurodevelopmental retardation is most marked, and she requires special schooling; despite initiation of treatment aged 6 or 8 weeks, respectively, P1a and P2 both exhibit mild neurodevelopmental impairment; in P1b, who was screened, diagnosed and treated at birth, neurological development was normal.</p>
<p>P3 exhibits a constellation of neurological deficits, much of which can be explained by early postnatal hypothyroxinaemia. Sensorineural hearing loss has been described in association with both primary and secondary hypothyroidism <xref ref-type="ref" rid="cen13149-bib-0003">3</xref>, <xref ref-type="ref" rid="cen13149-bib-0019">19</xref>, <xref ref-type="ref" rid="cen13149-bib-0020">20</xref> and reflects the essential role of thyroid hormone in the auditory development for maturation and innervation of cochlear hair cells, and development of central auditory pathways.<xref ref-type="ref" rid="cen13149-bib-0021">21</xref>, <xref ref-type="ref" rid="cen13149-bib-0022">22</xref> Additionally, nystagmus has been reported in the context of primary congenital hypothyroidism <xref ref-type="ref" rid="cen13149-bib-0023">23</xref>, <xref ref-type="ref" rid="cen13149-bib-0024">24</xref> and, given the importance of thyroid hormone in postnatal cerebellar granule cell development, may indicate defective maturation of cortico‐pontine‐cerebellar pathways.<xref ref-type="ref" rid="cen13149-bib-0025">25</xref> The complex neurodevelopmental abnormalities in P3 include autistic spectrum disorder, which, being reportedly associated with hypothyroxinaemia <italic>in utero</italic> rather than postnatally,<xref ref-type="ref" rid="cen13149-bib-0026">26</xref> might not be aetiologically linked to her congenital TSH deficiency, although a role for early postnatal hypothyroxinaemia may be plausible. Given the crucial postnatal role of thyroxine in the development of visuospatial, language and sensorimotor skills, central hypothyroidism is likely to have contributed to her neurodevelopmental delay.<xref ref-type="ref" rid="cen13149-bib-0025">25</xref>
</p>
<p>Our cases exhibit three different genetic aetiologies including one novel missense <italic>TSHB</italic> mutation (P3, c.2T&gt;C, p.Met1?). Mutation of a normal mammalian ATG start codon to ACG usually results in markedly diminished protein translation <xref ref-type="ref" rid="cen13149-bib-0027">27</xref> and thus would be expected to cause significantly reduced synthesis of full‐length TSHβ polypeptide from the mutant allele. Another in‐frame ATG codon, six residues downstream (Met‐7), is surrounded by an unfavourable nucleotide context for translational initiation, lacking both a purine at position ‐3 and a guanine at position +4.<xref ref-type="ref" rid="cen13149-bib-0016">16</xref> Even if limited TSHβ synthesis from Met‐7 occurred, this polypeptide would likely lack a recognizable signal sequence, compromising TSHβ processing and secretion.<xref ref-type="ref" rid="cen13149-bib-0017">17</xref> Consistent with such <italic>in silico</italic> predictions, <italic>in vivo</italic> data from P3 strongly suggest that negligible bioactive TSH is synthesized from the c.2T&gt;C allele, as profound hypothyroidism (undetectable fT4) is associated with barely measurable serum levels (0·45 mU/l) of intact TSH. Some of this TSH immunoreactivity may reflect translation of TSHβ from the residual c.373delT <italic>TSHB</italic> mutant allele, which is known to mediate the limited synthesis of biologically inactive TSH that retains immunoreactivity in some assays.<xref ref-type="ref" rid="cen13149-bib-0019">19</xref>
</p>
<p>P2 is the first recorded patient in whom a heterozygous deletion (5·4 kb, c.1‐4389_417*195delinsCTCA), encompassing <italic>TSHB</italic> alone, has been mapped precisely. Biallelic <italic>TSHB</italic> deletions were recently described in a Turkish patient.<xref ref-type="ref" rid="cen13149-bib-0013">13</xref> Intriguingly, one of the original Brazilian cases with a c.373delT <italic>TSHB</italic> mutation exhibited apparent uniparental inheritance; compound heterozygosity of the c.373delT mutation with a <italic>TSHB</italic> deletion would also be a plausible alternative explanation in this patient.<xref ref-type="ref" rid="cen13149-bib-0006">6</xref> P2 harbours a heterozygous <italic>TSHB</italic> deletion together with a monoallelic c.373delT mutation, suggesting that <italic>TSHB</italic> deletions may be a more common cause of isolated TSH deficiency than previously thought.</p>
<p>Worldwide, c.373delT is the commonest <italic>TSHB</italic> mutation reported, occurring in the unrelated cases from Western Europe, South America and the USA.<xref ref-type="ref" rid="cen13149-bib-0028">28</xref>, <xref ref-type="ref" rid="cen13149-bib-0029">29</xref>, <xref ref-type="ref" rid="cen13149-bib-0030">30</xref>, <xref ref-type="ref" rid="cen13149-bib-0031">31</xref> Accordingly, it is unsurprising that all of our cases harbour c.373delT <italic>TSHB</italic> either mono‐ or biallelically. Previous functional studies have shown that it is the cysteine to valine amino acid change at codon125, rather than subsequent deletion of 13 carboxyterminal residues of TSHβ, which impairs the function of mutant TSH.<xref ref-type="ref" rid="cen13149-bib-0006">6</xref> This amino acid substitution disrupts a disulphide bond between C125 and C39 that forms the ‘buckle’ of the TSHβ ‘seat belt’ which surrounds the αlpha subunit. Although the c.373delT mutation disrupts the functional integrity of TSH, alpha and mutant TSHβ subunits can still heterodimerize, forming biologically inactive TSH that retains immunoreactivity in some immunoassays.<xref ref-type="ref" rid="cen13149-bib-0019">19</xref> Consistent with this observation, the IMMULITE 2000 third‐generation immunoassay (Siemens) detects TSH in P2, albeit at inappropriately low levels. Although the c.373delT nucleotide change occurs at a mutation hot spot in <italic>TSHB</italic>, the gene defect is present as a founder mutation in some populations.<xref ref-type="ref" rid="cen13149-bib-0032">32</xref> Thus, analysis of our UK and Irish cases showed that the mutation also occured on a common (probably Irish) haplotype background in these families, supporting the notion of a founder effect.</p>
<p>Screening for congenital central hypothyroidism (CCH) can be achieved by inclusion of thyroxine (T4) plus thyroxine‐binding globulin (TBG), in the CH screening programme, as in the Netherlands or fT4 as in Japan. Combined T4/TSH/TBG evaluation in Dutch neonates enables diagnosis of permanent central CH with an incidence of 1:21 000 newborns.<xref ref-type="ref" rid="cen13149-bib-0033">33</xref> The incidence in Japan has been found to be much lower (1:160 000); however, although ethnic differences could be contributing, subsequent studies suggest this may reflect a less sensitive Japanese screening approach.<xref ref-type="ref" rid="cen13149-bib-0034">34</xref>, <xref ref-type="ref" rid="cen13149-bib-0035">35</xref>
</p>
<p>The benefits of including T4 measurement in CH screening continue to be debated with arguments against citing the relative rarity of congenital central hypothyroidism, with the presumption that it is usually mild and unlikely to be associated with adverse neurological sequelae. However, screening for CCH would enable prompt diagnosis and treatment of affected cases, improving neurodevelopmental outcomes particularly in severe cases due to <italic>TSHB</italic> mutations. Moreover, Zwaveling‐Soonawala <italic>et al</italic>. recently demonstrated that more than 50% of children diagnosed with CCH in the Netherlands exhibit moderate or severe hypothyroidism, rather than mild thyroid hormone deficits, thus emphasizing that the potential neurological sequelae of delayed diagnosis should not be underestimated (Zwaveling‐Soonawala <italic>et al</italic>. 2015).<xref ref-type="ref" rid="cen13149-bib-0036">36</xref> As combined pituitary hormone deficiencies occur in 75 per cent of CCH cases, early diagnosis of central hypothyroidism would also facilitate the prompt detection of pituitary–adrenal and growth hormone deficiencies, potentially preventing their life‐threatening consequences.<xref ref-type="ref" rid="cen13149-bib-0002">2</xref>
</p>
<p>We report the first cases from the UK and Ireland harbouring <italic>TSHB</italic> mutations, whose genetic aetiologies include a novel missense mutation, a compound heterozygous <italic>TSHB</italic> deletion and a known frameshift mutation. As well as expanding the known repertoire of <italic>TSHB</italic> mutations, our observations suggest that <italic>TSHB</italic> deletions may be more common than previously thought and show that c.373delT <italic>TSHB</italic> mutation is the most common genetic defect in cases of central hypothyroidism in the UK and Ireland. Concordant with other recorded cases, our patients with isolated TSH deficiency exhibit neurodevelopmental delay when overt hypothyroidism is diagnosed and treated later postnatally. As measurement of T4 is not included in UK or Ireland CH screening programmes, genetic ascertainment in families with isolated TSH deficiency will be particularly important, enabling prompt diagnosis of affected children and early treatment to prevent the adverse neurodevelopmental outcome.</p>
</sec>
<sec id="cen13149-sec-0022">
<title>Disclosure</title>
<p>Nothing to declare.</p>
</sec>
</body>
<back>
<ack id="cen13149-sec-0021">
<title>Acknowledgements</title>
<p>Our research is supported by funding from the Wellcome Trust (100585/Z/12/Z to NS, 095564/Z/11/Z to KC) and the National Institute for Health Research Biomedical Research Centre Cambridge (NS, KC).</p>
</ack>
<ref-list content-type="cited-references" id="cen13149-bibl-0001">
<title>References</title>
<ref id="cen13149-bib-0001">
<label>1</label>
<mixed-citation id="cen13149-cit-0001" publication-type="journal">
<string-name>
<surname>van Tijn</surname>, <given-names>D.A.</given-names>
</string-name>, <string-name>
<surname>de Vijlder</surname>, <given-names>J.J.</given-names>
</string-name>, <string-name>
<surname>Verbeeten</surname>, <given-names>B.</given-names>
<suffix>Jr</suffix>
</string-name>
<italic>et al</italic> (<year>2005</year>) <article-title>Neonatal detection of congenital hypothyroidism of central origin</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>90</volume>, <fpage>3350</fpage>–<lpage>3359</lpage>.<pub-id pub-id-type="pmid">15784706</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0002">
<label>2</label>
<mixed-citation id="cen13149-cit-0002" publication-type="journal">
<string-name>
<surname>Schoenmakers</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Alatzoglou</surname>, <given-names>K.S.</given-names>
</string-name>, <string-name>
<surname>Chatterjee</surname>, <given-names>V.K.</given-names>
</string-name>
<italic>et al</italic> (<year>2015</year>) <article-title>Recent advances in central congenital hypothyroidism</article-title>. <source/>Journal of Endocrinology, <volume>227</volume>, <fpage>R51</fpage>–<lpage>R71</lpage>.<pub-id pub-id-type="pmid">26416826</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0003">
<label>3</label>
<mixed-citation id="cen13149-cit-0003" publication-type="journal">
<string-name>
<surname>Baquedano</surname>, <given-names>M.S.</given-names>
</string-name>, <string-name>
<surname>Ciaccio</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Dujovne</surname>, <given-names>N.</given-names>
</string-name>
<italic>et al</italic> (<year>2010</year>) <article-title>Two novel mutations of the TSH‐beta subunit gene underlying congenital central hypothyroidism undetectable in neonatal TSH screening</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>95</volume>, <fpage>E98</fpage>–<lpage>E103</lpage>.<pub-id pub-id-type="pmid">20534762</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0004">
<label>4</label>
<mixed-citation id="cen13149-cit-0004" publication-type="journal">
<string-name>
<surname>Szkudlinski</surname>, <given-names>M.W.</given-names>
</string-name>, <string-name>
<surname>Fremont</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Ronin</surname>, <given-names>C.</given-names>
</string-name>
<italic>et al</italic> (<year>2002</year>) <article-title>Thyroid‐Stimulating Hormone and Thyroid‐Stimulating Hormone Receptor Structure‐Function Relationships</article-title>. <source/>Physiological Reviews, <volume>82</volume>, <fpage>473</fpage>–<lpage>502</lpage>.<pub-id pub-id-type="pmid">11917095</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0005">
<label>5</label>
<mixed-citation id="cen13149-cit-0005" publication-type="journal">
<string-name>
<surname>Hayashizaki</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Miyai</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Kato</surname>, <given-names>K.</given-names>
</string-name>
<italic>et al</italic> (<year>1985</year>) <article-title>Molecular cloning of the human thyrotropin‐beta subunit gene</article-title>. <source/>FEBS Letters, <volume>188</volume>, <fpage>394</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="pmid">3839756</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0006">
<label>6</label>
<mixed-citation id="cen13149-cit-0006" publication-type="journal">
<string-name>
<surname>Medeiros‐Neto</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Herodotou</surname>, <given-names>D.T.</given-names>
</string-name>, <string-name>
<surname>Rajan</surname>, <given-names>S.</given-names>
</string-name>
<italic>et al</italic> (<year>1996</year>) <article-title>A circulating, biologically inactive thyrotropin caused by a mutation in the beta subunit gene</article-title>. <source/>Journal of Clinical Investigation, <volume>97</volume>, <fpage>1250</fpage>–<lpage>1256</lpage>.<pub-id pub-id-type="pmid">8636437</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0007">
<label>7</label>
<mixed-citation id="cen13149-cit-0007" publication-type="journal">
<string-name>
<surname>Sertedaki</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Papadimitriou</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Voutetakis</surname>, <given-names>A.</given-names>
</string-name>
<italic>et al</italic> (<year>2002</year>) <article-title>Low TSH congenital hypothyroidism: identification of a novel mutation of the TSH beta‐subunit gene in one sporadic case (C85R) and of mutation Q49stop in two siblings with congenital hypothyroidism</article-title>. <source/>Pediatric Research, <volume>52</volume>, <fpage>935</fpage>–<lpage>941</lpage>.<pub-id pub-id-type="pmid">12438673</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0008">
<label>8</label>
<mixed-citation id="cen13149-cit-0008" publication-type="journal">
<string-name>
<surname>Hayashizaki</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Hiraoka</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Endo</surname>, <given-names>Y.</given-names>
</string-name>
<italic>et al</italic> (<year>1989</year>) <article-title>Thyroid‐stimulating hormone (TSH) deficiency caused by a single base substitution in the CAGYC region of the beta‐subunit</article-title>. <source/>The EMBO Journal, <volume>8</volume>, <fpage>2291</fpage>–<lpage>2296</lpage>.<pub-id pub-id-type="pmid">2792087</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0009">
<label>9</label>
<mixed-citation id="cen13149-cit-0009" publication-type="journal">
<string-name>
<surname>Vuissoz</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Deladoëy</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Buyukgebiz</surname>, <given-names>A.</given-names>
</string-name>
<italic>et al</italic> (<year>2001</year>) <article-title>New autosomal recessive mutation of the TSH‐beta subunit gene causing central isolated hypothyroidism</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>86</volume>, <fpage>4468</fpage>–<lpage>4471</lpage>.<pub-id pub-id-type="pmid">11549695</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0010">
<label>10</label>
<mixed-citation id="cen13149-cit-0010" publication-type="journal">
<string-name>
<surname>Dacou‐Voutetakis</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Feltquate</surname>, <given-names>D.M.</given-names>
</string-name>, <string-name>
<surname>Drakopoulou</surname>, <given-names>M.</given-names>
</string-name>
<italic>et al</italic> (<year>1990</year>) <article-title>Familial hypothyroidism caused by a nonsense mutation in the thyroid‐stimulating hormone beta‐subunit gene</article-title>. <source/>The American Journal of Human Genetics, <volume>46</volume>, <fpage>988</fpage>–<lpage>993</lpage>.<pub-id pub-id-type="pmid">1971148</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0011">
<label>11</label>
<mixed-citation id="cen13149-cit-0011" publication-type="journal">
<string-name>
<surname>Morales</surname>, <given-names>A.E.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>J.D.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>C.Y.</given-names>
</string-name>
<italic>et al</italic> (<year>2004</year>) <article-title>Novel TSHbeta subunit gene mutation causing congenital central hypothyroidism in a newborn male</article-title>. <source/>Journal of Pediatric Endocrinology and Metabolism, <volume>17</volume>, <fpage>355</fpage>–<lpage>359</lpage>.<pub-id pub-id-type="pmid">15112912</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0012">
<label>12</label>
<mixed-citation id="cen13149-cit-0012" publication-type="journal">
<string-name>
<surname>Borck</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Topaloglu</surname>, <given-names>A.K.</given-names>
</string-name>, <string-name>
<surname>Korsch</surname>, <given-names>E.</given-names>
</string-name>
<italic>et al</italic> (<year>2004</year>) <article-title>Four new cases of congenital secondary hypothyroidism due to a splice site mutation in the thyrotropin‐beta gene: phenotypic variability and founder effect</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>89</volume>, <fpage>4136</fpage>–<lpage>4141</lpage>.<pub-id pub-id-type="pmid">15292359</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0013">
<label>13</label>
<mixed-citation id="cen13149-cit-0013" publication-type="journal">
<string-name>
<surname>Hermanns</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Couch</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>, <given-names>N.</given-names>
</string-name>
<italic>et al</italic> (<year>2014</year>) <article-title>A novel deletion in the thyrotropin Beta‐subunit gene identified by array comparative genomic hybridization analysis causes central congenital hypothyroidism in a boy originating from Turkey</article-title>. <source/>Hormone Research in Paediatrics, <volume>82</volume>, <fpage>201</fpage>–<lpage>205</lpage>.<pub-id pub-id-type="pmid">25012771</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0014">
<label>14</label>
<mixed-citation id="cen13149-cit-0014" publication-type="journal">
<string-name>
<surname>Petersen</surname>, <given-names>T.N.</given-names>
</string-name>, <string-name>
<surname>Brunak</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>von Heijne</surname>, <given-names>G.</given-names>
</string-name>
<italic>et al</italic> (<year>2011</year>) <article-title>SignalP 4.0: discriminating signal peptides from transmembrane regions</article-title>. <source/>Nature Methods, <volume>8</volume>, <fpage>785</fpage>–<lpage>786</lpage>.<pub-id pub-id-type="pmid">21959131</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0015">
<label>15</label>
<mixed-citation id="cen13149-cit-0015" publication-type="journal">
<string-name>
<surname>Agostini</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Schoenmakers</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>, <given-names>C.S.</given-names>
</string-name>
<italic>et al</italic> (<year>2006</year>) <article-title>Non‐DNA binding, dominant negative human PPARγ mutations causes lipodystrophic insulin resistance</article-title>. <source/>Cell Metabolism, <volume>4</volume>, <fpage>303</fpage>–<lpage>311</lpage>.<pub-id pub-id-type="pmid">17011503</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0016">
<label>16</label>
<mixed-citation id="cen13149-cit-0016" publication-type="journal">
<string-name>
<surname>Kozak</surname>, <given-names>M.</given-names>
</string-name> (<year>1989</year>) <article-title>The scanning model for translation: an update</article-title>. <source/>Journal of Cell Biology, <volume>108</volume>, <fpage>229</fpage>–<lpage>241</lpage>.<pub-id pub-id-type="pmid">2645293</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0017">
<label>17</label>
<mixed-citation id="cen13149-cit-0017" publication-type="journal">
<string-name>
<surname>Hatsuzawa</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Tagaya</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name>
<surname>Mizushima</surname>, <given-names>S.</given-names>
</string-name> (<year>1997</year>) <article-title>The hydrophobic region of signal peptides is a determinant for SRP recognition and protein translocation across the ER membrane</article-title>. <source/>Journal of Biochemistry, <volume>121</volume>, <fpage>270</fpage>–<lpage>277</lpage>.<pub-id pub-id-type="pmid">9089400</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0018">
<label>18</label>
<mixed-citation id="cen13149-cit-0018" publication-type="journal">
<string-name>
<surname>Felner</surname>, <given-names>E.I.</given-names>
</string-name>, <string-name>
<surname>Dickson</surname>, <given-names>B.A.</given-names>
</string-name> &amp; <string-name>
<surname>White</surname>, <given-names>P.C.</given-names>
</string-name> (<year>2004</year>) <article-title>Hypothyroidism in siblings due to a homozygous mutation of the TSH‐beta subunit gene</article-title>. <source/>Journal of Pediatric Endocrinology and Metabolism, <volume>17</volume>, <fpage>669</fpage>–<lpage>672</lpage>.<pub-id pub-id-type="pmid">15198300</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0019">
<label>19</label>
<mixed-citation id="cen13149-cit-0019" publication-type="journal">
<string-name>
<surname>Bonomi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Proverbio</surname>, <given-names>M.C.</given-names>
</string-name>, <string-name>
<surname>Weber</surname>, <given-names>G.</given-names>
</string-name>
<italic>et al</italic> (<year>2001</year>) <article-title>Hyperplastic pituitary gland, high serum glycoprotein hormone alpha‐subunit, and variable circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>86</volume>, <fpage>1600</fpage>–<lpage>1604</lpage>.<pub-id pub-id-type="pmid">11297590</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0020">
<label>20</label>
<mixed-citation id="cen13149-cit-0020" publication-type="journal">
<string-name>
<surname>Lichtenberger‐Geslin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Dos Santos</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hassani</surname>, <given-names>Y.</given-names>
</string-name>
<italic>et al</italic> (<year>2013</year>) <article-title>Factors associated with hearing impairment in patients with congenital hypothyroidism treated since the neonatal period: a national population‐based study</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>98</volume>, <fpage>3644</fpage>–<lpage>3652</lpage>.<pub-id pub-id-type="pmid">23780375</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0021">
<label>21</label>
<mixed-citation id="cen13149-cit-0021" publication-type="journal">
<string-name>
<surname>Ng</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Kelley</surname>, <given-names>M.W.</given-names>
</string-name> &amp; <string-name>
<surname>Forrest</surname>, <given-names>D.</given-names>
</string-name> (<year>2013</year>) <article-title>Making sense with thyroid hormone–the role of T(3) in auditory development</article-title>. <source/>Nature Reviews Endocrinology, <volume>9</volume>, <fpage>296</fpage>–<lpage>307</lpage>.</mixed-citation>
</ref>
<ref id="cen13149-bib-0022">
<label>22</label>
<mixed-citation id="cen13149-cit-0022" publication-type="journal">
<string-name>
<surname>Rüsch</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Erway</surname>, <given-names>L.C.</given-names>
</string-name>, <string-name>
<surname>Oliver</surname>, <given-names>D.</given-names>
</string-name>
<italic>et al</italic> (<year>1998</year>) <article-title>Thyroid hormone receptor beta‐dependent expression of a potassium conductance in inner hair cells at the onset of hearing</article-title>. <source/>Proceedings of the National Academy of Sciences USA, <volume>95</volume>, <fpage>15758</fpage>–<lpage>15762</lpage>.</mixed-citation>
</ref>
<ref id="cen13149-bib-0023">
<label>23</label>
<mixed-citation id="cen13149-cit-0023" publication-type="journal">
<string-name>
<surname>Macfaul</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Dorner</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Brett</surname>, <given-names>E.M.</given-names>
</string-name>
<italic>et al</italic> (<year>1978</year>) <article-title>Neurological abnormalities in patients treated for hypothyroidism from early life</article-title>. <source/>Archives of Disease in Childhood, <volume>53</volume>, <fpage>611</fpage>–<lpage>619</lpage>.<pub-id pub-id-type="pmid">708096</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0024">
<label>24</label>
<mixed-citation id="cen13149-cit-0024" publication-type="journal">
<string-name>
<surname>Schulman</surname>, <given-names>J.D.</given-names>
</string-name> &amp; <string-name>
<surname>Crawford</surname>, <given-names>J.D.</given-names>
</string-name> (<year>1969</year>) <article-title>Congenital nystagmus and hypothyroidism</article-title>. <source/>New England Journal of Medicine, <volume>280</volume>, <fpage>708</fpage>–<lpage>710</lpage>.<pub-id pub-id-type="pmid">5766079</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0025">
<label>25</label>
<mixed-citation id="cen13149-cit-0025" publication-type="journal">
<string-name>
<surname>Zoeller</surname>, <given-names>R.T.</given-names>
</string-name> &amp; <string-name>
<surname>Rovet</surname>, <given-names>J.</given-names>
</string-name> (<year>2004</year>) <article-title>Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings</article-title>. <source/>Journal of Neuroendocrinology
<volume>16</volume>, <fpage>809</fpage>–<lpage>818</lpage>. Review.<pub-id pub-id-type="pmid">15500540</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0026">
<label>26</label>
<mixed-citation id="cen13149-cit-0026" publication-type="journal">
<string-name>
<surname>Berbel</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Navarro</surname>, <given-names>D.</given-names>
</string-name> &amp; <string-name>
<surname>Roman</surname>, <given-names>G.C.</given-names>
</string-name> (<year>2014</year>) <article-title>An evo‐devo approach to thyroid hormones in cerebral and cerebellar cortical development: etiological implications for autism</article-title>. <source/>Frontiers in Endocrinology (Lausanne), <volume>9</volume>, <fpage>146</fpage>. doi:<ext-link ext-link-type="doi" xlink:href="10.3389/fendo.2014.00146">10.3389/fendo.2014.00146</ext-link>.</mixed-citation>
</ref>
<ref id="cen13149-bib-0027">
<label>27</label>
<mixed-citation id="cen13149-cit-0027" publication-type="journal">
<string-name>
<surname>Hinnebusch</surname>, <given-names>A.G.</given-names>
</string-name> (<year>2011</year>) <article-title>Molecular mechanism of scanning and start codon selection in eukaryotes</article-title>. <source/>Microbiology and Molecular Biology Reviews, <volume>75</volume>, <fpage>434</fpage>–<lpage>467</lpage>.<pub-id pub-id-type="pmid">21885680</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0028">
<label>28</label>
<mixed-citation id="cen13149-cit-0028" publication-type="journal">
<string-name>
<surname>Deladoëy</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Vuissoz</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Domené</surname>, <given-names>H.M.</given-names>
</string-name>
<italic>et al</italic> (<year>2003</year>) <article-title>Congenital secondary hypothyroidism due to a mutation C105Vfs114X thyrotropin‐beta mutation: genetic study of five unrelated families from Switzerland and Argentina</article-title>. <source/>Thyroid, <volume>13</volume>, <fpage>553</fpage>–<lpage>559</lpage>.<pub-id pub-id-type="pmid">12930599</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0029">
<label>29</label>
<mixed-citation id="cen13149-cit-0029" publication-type="journal">
<string-name>
<surname>Domene</surname>, <given-names>H.M.</given-names>
</string-name>, <string-name>
<surname>Gruneiro‐Papendieck</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Chiesa</surname>, <given-names>A.</given-names>
</string-name>
<italic>et al</italic> (<year>2004</year>) <article-title>The C105fs114X Is the Prevalent Thyrotropin Beta‐Subunit Gene Mutation in Argentinean Patients with Congenital Central Hypothyroidism</article-title>. <source/>Hormone Research, <volume>61</volume>, <fpage>41</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">14646401</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0030">
<label>30</label>
<mixed-citation id="cen13149-cit-0030" publication-type="journal">
<string-name>
<surname>Karges</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>LeHeup</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Schoenle</surname>, <given-names>E.</given-names>
</string-name>
<italic>et al</italic> (<year>2004</year>) <article-title>Compound heterozygous and homozygous mutations of the TSHbeta gene as a cause of congenital central hypothyroidism in Europe</article-title>. <source/>Hormone Research, <volume>62</volume>, <fpage>149</fpage>–<lpage>155</lpage>.</mixed-citation>
</ref>
<ref id="cen13149-bib-0031">
<label>31</label>
<mixed-citation id="cen13149-cit-0031" publication-type="journal">
<string-name>
<surname>McDermott</surname>, <given-names>M.T.</given-names>
</string-name>, <string-name>
<surname>Haugen</surname>, <given-names>B.R.</given-names>
</string-name>, <string-name>
<surname>Black</surname>, <given-names>J.N.</given-names>
</string-name>
<italic>et al</italic> (<year>2002</year>) <article-title>Congenital isolated central hypothyroidism caused by a “hot spot” mutation in the thyrotropin‐beta gene</article-title>. <source/>Thyroid, <volume>12</volume>, <fpage>1141</fpage>–<lpage>1146</lpage>.<pub-id pub-id-type="pmid">12593729</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0032">
<label>32</label>
<mixed-citation id="cen13149-cit-0032" publication-type="journal">
<string-name>
<surname>Brumm</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Pfeufer</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Biebermann</surname>, <given-names>H.</given-names>
</string-name>
<italic>et al</italic> (<year>2002</year>) <article-title>Congenital central hypothyroidism due to homozygous thyrotropin beta 313deltaT mutation is caused by a founder effect</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>87</volume>, <fpage>4811</fpage>–<lpage>4816</lpage>.<pub-id pub-id-type="pmid">12364478</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0033">
<label>33</label>
<mixed-citation id="cen13149-cit-0033" publication-type="journal">
<string-name>
<surname>Kempers</surname>, <given-names>M.J.</given-names>
</string-name>, <string-name>
<surname>Lanting</surname>, <given-names>C.I.</given-names>
</string-name>, <string-name>
<surname>van Heijst</surname>, <given-names>A.F.</given-names>
</string-name>
<italic>et al</italic> (<year>2006</year>) <article-title>Neonatal screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine‐binding globulin measurement: potentials and pitfalls</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>91</volume>, <fpage>3370</fpage>–<lpage>3376</lpage>.<pub-id pub-id-type="pmid">16787990</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0034">
<label>34</label>
<mixed-citation id="cen13149-cit-0034" publication-type="journal">
<string-name>
<surname>Asakura</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Tachibana</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Adachi</surname>, <given-names>M.</given-names>
</string-name>
<italic>et al</italic> (<year>2002</year>) <article-title>Hypothalamo‐pituitary hypothyroidism detected by neonatal screening for congenital hypothyroidism using measurement of thyroid‐stimulating hormone and thyroxine</article-title>. <source/>Acta Paediatrica, <volume>91</volume>, <fpage>172</fpage>–<lpage>177</lpage>.<pub-id pub-id-type="pmid">11952005</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0035">
<label>35</label>
<mixed-citation id="cen13149-cit-0035" publication-type="journal">
<string-name>
<surname>Adachi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Soneda</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Asakura</surname>, <given-names>Y.</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>Mass screening of newborns for congenital hypothyroidism of central origin by free thyroxine measurement of blood samples on filter paper</article-title>. <source/>European Journal of Endocrinology, <volume>166</volume>, <fpage>829</fpage>–<lpage>838</lpage>.<pub-id pub-id-type="pmid">22301913</pub-id></mixed-citation>
</ref>
<ref id="cen13149-bib-0036">
<label>36</label>
<mixed-citation id="cen13149-cit-0036" publication-type="journal">
<string-name>
<surname>Zwaveling‐Soonawala</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>van Trotsenburg</surname>, <given-names>A.S.</given-names>
</string-name> &amp; <string-name>
<surname>Verkerk</surname>, <given-names>P.H.</given-names>
</string-name> (<year>2015</year>) <article-title>The severity of congenital hypothyroidism of central origin should not be underestimated</article-title>. <source/>Journal of Clinical Endocrinology and Metabolism, <volume>100</volume>, <fpage>E297</fpage>–<lpage>E300</lpage>.<pub-id pub-id-type="pmid">25347570</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>